Navigation Links
Wyeth Reports Earnings Results for the 2007 Fourth Quarter and Full Year
Date:1/31/2008

ncome

Taxes 1,426,932 1,158,434 6,730,082 5,648,484

Provision for Income

Taxes(3) 367,602 254,994 1,919,722 1,367,703

Net Income(3) $1,059,330 $903,440 $4,810,360 $4,280,781

Basic Earnings Per

Share(2) $0.79 $0.67 $3.58 $3.18

Average Number of Common

Shares Outstanding During

Each Period - Basic 1,338,559 1,346,087 1,342,552 1,345,386

Diluted Earnings Per

Share(2) $0.78 $0.66 $3.52 $3.14

Average Number of Common

Shares Outstanding During

Each Period - Diluted 1,367,895 1,379,180 1,374,342 1,374,053

See Notes to Results of Operations and Results of Operations -- As Adjusted.

Notes to Results of Operations and Results of Operations -- As Adjusted

(1) Other income, net included royalty income for the 2007 fourth quarter

and full year of $58,351 and $260,399, respectively, compared with

$68,764 and $262,628 for the prior year.

(2) The average number of common shares outstanding for diluted earnings

per share is higher than for basic earnings per share due to the

assumed conversion of the Company's outstanding convertible senior

debentures, outstanding stock options, deferred contingent common

stock awards, performance share awards, restricted stock awards and

convertible preferred stock into common stock equivalents using the

treasury stock method. For purposes of calculating diluted earnings

per share, interest expense, net of capitalized interest and taxes

related to the Company's outstanding convertible senior debentures is

added back to reported net income, and the additional common shares

(assuming conversion) are included in total shares ou
'/>"/>

SOURCE Wyeth
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
2. Wyeth Announces $5 Billion Share Repurchase Program; Declares Increase in Common Stock Dividend
3. Wyeth Pharmaceuticals Acquires Haptogen Ltd. to Boost Biotechnology Drug Discovery
4. Wyeth Announces Election of New Principal Corporate Officer
5. Wyeth Declares Preferred Stock Dividend
6. Raven biotechnologies, inc. and Wyeth Pharmaceuticals Extend Evaluation Period of Selected Raven Antibodies
7. Wyeth Provides Update on Regulatory Review of Viviant (bazedoxifene)
8. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
9. Wyeth Will Pursue Claim for Damages Resulting From Teva Pharmaceuticals Launch of Generic Pantoprazole in Violation of PROTONIX Patent
10. Wyeth Consumer Healthcare Supports U.S. Food and Drug Administration Decision for Over-the-Counter Cough and Cold Medications in Children under Two Years of Age
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... Carolina (PRWEB) May 01, 2015 Spirax ... services, is extremely proud to announce that for the ... named as a winner of a Queen’s Award for ... for the design and manufacture of a unique flowmeter. ... the revolutionary alternative to traditional steam flow measurement. ...
(Date:4/30/2015)... 30, 2015   Tamir Biotechnology , a leading ... on its Ebola antiviral therapy program. ... is currently being evaluated and considered by a number ... Ebola. During the first quarter of 2015, the company ... Accelerate The Evaluation of Potential Treatments and Vaccines For ...
(Date:4/30/2015)... MINNEAPOLIS, MN , April 30, 2015 /PRNewswire/ - ... company producing sustainable chemicals, today announced that it has commenced ... addition, BioAmber expects to grant the underwriters a 30-day ... of the shares of common stock offered in the ... and there can be no assurance as to whether ...
(Date:4/30/2015)... 2015 Oxford Finance LLC ("Oxford"), a specialty ... and healthcare services companies, today announced the closing of ... Celula, Inc., a diagnostic testing company focused on improving ... care and improved outcomes.  Proceeds of the loan will ... commercialization of its products in the U.S. and ...
Breaking Biology Technology:Spirax Sarco Receives a Queen’s Award for Innovation 2Spirax Sarco Receives a Queen’s Award for Innovation 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4BioAmber Inc. Announces Public Offering Of Common Stock 2BioAmber Inc. Announces Public Offering Of Common Stock 3Oxford Finance Provides $10 Million Debt Financing to Celula 2
... Sept. 18 Caliper Life,Sciences, Inc. (Nasdaq: ... the,UBS Global Life Sciences Conference in New York ... at 3:30 p.m. EDT. Kevin Hrusovsky, President,and CEO ... the company,s business.,The audio-only webcast can be accessed ...
... /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), a biotechnology ... therapeutics, today announced that ARIUS Research Inc.,shareholders and ... the Company and Roche., At a special ... ARIUS,shareholders and warrant holders approved the transaction, with ...
... MADISON, Wis., Sept. 18 Cellectar, Inc., a,privately-held ... treat and monitor human cancers, today announced the,appointment ... Board of,Directors., Mr. Harwood, 55, is a ... private equity firm. Prior to working with Avista,Mr. ...
Cached Biology Technology:ARIUS sale approved by shareholders 2Charles C. Harwood, Jr., Joins Cellectar, Inc.'s Board of Directors 2
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/2/2015)... , April 2, 2015 At its ... Salt Lake City , the American College of ... five new directors to its Board.  Members of the ... ACMG and for forming and advancing its policies and ... genetics profession. "It,s an eventful time in ...
(Date:3/31/2015)...  Elephant Talk Communications Corp. (NYSE MKT: ETAK) ("Elephant ... Defined Network Architecture (ET Software DNA® 2.0) platforms and ... $20.4 million for the year ended December 31, 2014 ... year ended December 31, 2013. At ... its multi-year transition away from its legacy landline business ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6
... A class of Alzheimer,s disease drugs currently studied ... traumatic brain injury in animals, researchers at Georgetown University ... of Nature Medicine . They say the ... do something no other drug has been able to ...
... a common feature of prion disease-affected human, mouse, and ... Neena Singh and colleagues at Case Western Reserve University ... findings, published March 13 in the open-access journal ... of neurotoxicity in prion disorders, and novel avenues for ...
... consumption are undisputable, although some data suggest that ... For instance, several studies have reported a positive ... (BMD) in older women. There are fewer studies ... and none have considered different classes of alcoholic ...
Cached Biology News:Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 2Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies 3Iron is involved in prion disease-associated neuronal demise 2
MOUSE ANTI BOVINE CD335:ALEXA 488 Immunogen: Fusion protein consisting of the extracellular region of bovine CD335....
... Kit is intended for the derivation ... blastocysts in serum-free conditions. ... Clonal Grade Medium Basal Medium ... Trypsin Solution Gelatin Solution Complete ...
RABBIT ANTI TRANSFERRIN RECEPTOR...
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
Biology Products: